Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.
Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.
StrongSupportsHIGH confidence
In the SURMOUNT-1 trial... tirzepatide was associated with a decrease in body weight of 15 %, 19.5 %, and 20.9 % at a dose of 5 mg, 10 mg, and 15 mg, respectively, from baseline to week 72 compared to placebo
Why this rating
Based on Phase III SURMOUNT-1 trial data cited in the review.
Source
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
François Schiele et al. · American Journal of Preventive Cardiology · 2025
DOI 10.1016/j.ajpc.2025.100987
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.Strong
- Metabolic bariatric surgery is the most effective treatment for obesity across all BMI classes, offering durable weight loss and improvement in comorbidities.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →